The pharmaceutical market in Europe was valued at approximately USD 488.05 billion in 2024 and is expected to grow steadily at a compound annual growth rate (CAGR) of 5.90% from 2025 through 2030. Several key factors are driving this market expansion. These include the region’s aging population, which increases the demand for healthcare products and services, as well as continuous advancements in medical technology. Rising healthcare expenditure across European countries also plays a significant role. Additionally, the growing prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer has heightened the need for effective treatment options. Access to innovative medicines, streamlined regulatory processes that expedite drug approvals, and an increasing focus on preventive healthcare further contribute to the overall growth. Government-led initiatives aimed at improving public health and the rapid adoption of digital health technologies are also important supportive factors in this evolving landscape.

Strategic partnerships and sustained investments in research and development (RD) continue to be critical drivers for innovation within the pharmaceutical sector. These collaborations enable companies to develop new and improved products, thereby enhancing their competitive positioning in the market. The European pharmaceutical industry is heavily influenced by breakthroughs in medical technology, particularly in the fields of biotechnology and advanced drug development. Cutting-edge therapies such as CAR-T cell therapy, gene therapy, and sophisticated biologics have transformed disease treatment paradigms, offering more targeted, efficient, and less invasive options for patients. Biopharmaceuticals — including monoclonal antibodies, immunotherapies, and cell-based therapies — have been pivotal in treating complex diseases such as cancer, autoimmune disorders, and rare genetic conditions. The industry pipeline is focused on continuous innovation with products like biologics, biosimilars, immunotherapies, and novel drug delivery systems that span multiple therapeutic areas. Through ongoing development and approval of these advanced treatments, patients gain access to personalized and highly effective care. A notable trend is the increased emphasis on orphan drugs targeting rare and underserved diseases, which has accelerated the development of new therapies and influenced regulatory frameworks to facilitate quicker approvals.

The European Medicines Agency (EMA) plays a crucial role in this ecosystem by streamlining the drug approval process. This regulatory body ensures that patients receive timely access to innovative therapies while upholding strict safety and efficacy standards. The regulatory environment in Europe promotes active collaboration between pharmaceutical companies and regulatory authorities, which speeds up the development, assessment, and commercialization of novel medicines. According to a report published in 2024 by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in partnership with IQVIA, an overview of the clinical trial landscape highlights the number and distribution of ongoing clinical drug trials across European countries as of March 2025. This data underscores the dynamic research environment and continued commitment to advancing pharmaceutical science in the region.

Key Market Trends Insights:

• By molecule type, conventional drugs, also known as small molecules, held a dominant position in the pharmaceutical market in 2024, capturing the largest share of 54.74%. This indicates that a majority of the market revenue was generated from traditional, chemically synthesized medications.

• When considering product categories, the branded segment led the market, accounting for a significant revenue share of 66.49% in 2024. This suggests that patented and brand-name drugs contributed substantially more to market earnings compared to generic alternatives.

• Looking at the type of medication, the prescription segment held the lion’s share of the market in 2024, with revenues constituting 86.76%. This highlights the predominance of drugs that require a healthcare professional’s authorization for use, underscoring their critical role in treatment protocols.

• Focusing on diseases, the cancer segment emerged as the leading category in terms of revenue share in 2024, contributing 18.06%. This reflects the substantial investment and demand for oncology therapies within the pharmaceutical landscape.

• Regarding the route of administration, oral delivery of drugs was a major revenue contributor in 2024, accounting for 57.53% of the market share. This underscores the preference for oral medications due to their convenience, ease of use, and widespread acceptance among patients.

Order a free sample PDF of the Europe Pharmaceutical Market Intelligence Study, published by Grand View Research.

Market Size Forecast:

• 2024 Market Size: USD 488.05 Billion

• 2030 Projected Market Size: USD 688.44 Billion

• CAGR (2025-2030): 5.90% 

Key Companies Market Share Insights:

Leading companies within Europe’s pharmaceutical and drug development industries are primarily focused on innovation and continuous improvement of existing technologies to significantly improve patient outcomes and overall healthcare efficiency. Their initiatives include advancing the formulation of drugs to increase effectiveness, optimizing drug delivery systems to ensure better targeting and absorption, and expanding the range of therapeutic applications to treat a broader spectrum of diseases. With a strong emphasis on research and development (RD), these companies dedicate substantial resources to discovering new solutions that address unmet medical needs in various patient populations.

Key Players

• F. Hoffmann-La Roche Ltd.

• Bristol-Myers Squibb Company

• AstraZeneca plc

• Novartis AG

• Johnson Johnson Services, Inc.

• Gilead Sciences, Inc.

• GlaxoSmithKline plc.

• Merck Co., Inc.

• Pfizer Inc.

• Sanofi

• Boehringer Ingelheim GmbH

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The European pharmaceutical market is projected to experience steady growth, driven by factors such as an aging population, advancements in medical technology, and increased healthcare spending. The market is characterized by a strong presence of branded drugs, with the generic segment anticipated to grow at a faster rate due to patent expirations and cost-efficiency demands. Research and development efforts remain central to the industry's progress, with significant investments aimed at introducing novel therapies and improving existing treatments. Regulatory bodies play a crucial role in ensuring the safety and efficacy of new medications, thereby fostering innovation and maintaining high standards within the market.